Press Releases

GlobeNewswire, Inc.

CALABASAS, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today...

GlobeNewswire, Inc.

MCLEAN, Va., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Appian (Nasdaq: APPN) today announced financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights: Revenue: Cloud subscriptions revenue was $136.4...

GlobeNewswire, Inc.

AUSTIN, Texas, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Commerce.com, Inc. (Nasdaq: CMRC), the open commerce ecosystem built to help merchants win as AI reshapes how customers discover and buy, today announced financial results for its third quarter...

GlobeNewswire, Inc.

LOS ANGELES, Nov. 05, 2026 (GLOBE NEWSWIRE) -- ServiceTitan, Inc. (Nasdaq: TTAN), the software platform that powers the trades, today announced that it will report its financial results for the fiscal third quarter ended October 31, 2026 after...

GlobeNewswire, Inc.

PHILADELPHIA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of MNTN, Inc. ("MNTN" or the "Company") (NYSE: MNTN) following the Company’s November 4, 2026 disclosures...

GlobeNewswire, Inc.

Mountain View, CA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Open Enrollment for 2027 health coverage is underway, and Vimo® is encouraging consumers to compare plans and check their eligibility for financial assistance before renewing or choosing...

GlobeNewswire, Inc.

- Completed the Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy, top-line results to be announced in November 2026 - - Phase 2b Long-Term Extension Study fully recruited, 95 patients enrolled, assessing Halneuron® reduction in pain...

GlobeNewswire, Inc.

Pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints Bitopertin NDA resubmission planned by end of 2026, with an FDA decision for potential approval in EPP...

GlobeNewswire, Inc.

Completed Phase 1 study of SCY-770, a first-in-class, highly selective, oral direct AMPK activator for the treatment of ADPKD; Phase 2 proof-of-concept trial to initiate in Q4 2026 Awarded BARDA contract providing up to approximately $214 million...

GlobeNewswire, Inc.

Revenues of $88.2 million, an increase of $29.0 million (49%) over the third quarter of 2025 Aemetis Biogas RNG sales volume grew 39% to 158,200 MMBtu, compared with 114,000 MMBtu in the third quarter of 2025 Operating income of $20.9 million...

GlobeNewswire, Inc.

SCOTTSDALE, Ariz., Nov. 05, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the third quarter ended September 30,...

GlobeNewswire, Inc.

Successful satellite launch, key regulatory approvals, and strong Commercial IoT device sales highlight third-quarter achievements Generated third quarter 2026 revenue of $70.9 million with another quarter of strong Commercial IoT subscriber...

EIN Presswire

JD Credit explains how a bank Debt Consolidation Plan, a consolidation loan and free credit counselling differ, and how to test which one helps.

GlobeNewswire, Inc.

GREENWICH, Conn., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS: OXLCN) (NasdaqGS: OXLCI) (NasdaqGS: OXLCG) (NasdaqGS: OXLCM) (“Oxford Lane,” the...

GlobeNewswire, Inc.

On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date New lonvo-z patient perspectives and Phase 1/2 durability data to be included in investor webcast and multiple presentations next week at ACAAI 2026...

GlobeNewswire, Inc.

– Initiated the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in Crohn’s disease; 12-week induction data expected in the first half of 2028 – – Announced RECEPTIVE-HS1 Phase 2 clinical trial of SL-325 in hidradenitis suppurativa; trial...

GlobeNewswire, Inc.

– Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hold – Recent publication in Cells1 provides new insights into simufilam’s potential mechanism of action...

GlobeNewswire, Inc.

Total Revenue Growth of 26% to $85.4 Million Net Income Increased 179% to $14.2 Million Adjusted EBITDA Margin of 30% Raised Full-Year Revenue Guidance to $344 to $346 Million and Adjusted EBITDA Margin Guidance to 28% Conference Call Today at...

GlobeNewswire, Inc.

PURCHASE, N.Y., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial...

GlobeNewswire, Inc.

– Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Generated AZSTARYS® Quarterly Net Revenue of $26.5 Million in First...